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Ovarian carcinoma is now the leading cause ofdeath amongwomen. Surgery has reached its
limits, and further aggressive surgery will result in an inordinate morbidity and mortality.
Ovarian carcinoma is ideally treated bycomplete surgical removal ofthe cancer, followed by
anti-cancer chemotherapy. Since it is often impossible to remove all of the cancer, adjunctive
chemotherapy is playing an increasingly important role in the management ofthe cancer. New
anti-cancer drugs must be found or synthesized, and new combinations of current anti-cancer
drugswith mechanisms to protect the bone marrow must be explored.
The field of genetics and the identification of the patient at high risk because of a familial
history ofovarian cancer mustbe expanded.
The role of tumor markers and oncogenes requires more in-depth study so that these signs
can play a greater role in monitoring and identifying the patient with earlyovarian cancer.
The emerging fields ofgenetic engineering and biologic response modifiers are opening up
new avenues for additional modalities oftherapy.
The expanding areas of research in cancer are starting to dispel the doom and gloom of the
last three decadeswith aspirit ofoptimismforthe diagnosis and treatment ofovarian cancer, as
the new century approaches.
Great strides have been made, in the last two decades, in understanding basic
cellular functions. This knowledge is the keystone in structuring a program to
identify the patient at high risk, formulating tests for making an early diagnosis, and
treating the cancer onguidelines established through this research.
It is estimated that there will be 20,700 new cases of carcinoma of the ovary
diagnosed in 1991, with approximately 12,500 deaths [1,2]. This fact means that
approximately one woman in 70 at some time in her life will develop an ovarian
tumor. The tragedy is that in each decade more than 100,000 women at the height of
their economic and social productivity will die from this dread disease. Although
progress has been made in diagnosing and treating ovarian cancer, the discouraging
127
Abbreviations: AFP: alpha-fetoprotein CA125: cancer antigen 125 CCD: cell cycle distribution
CEA:carcinoembryonic antigen DCT: DivisionofCancerTreatment, NationalCancerInstitute DDTC:
diethyldithocarbamate DI: DNAindex DM/70KorNB/70K: Dianon markerNB/70K EGFR: epider-
mal growth factor receptor ER: estrogen receptor FCM: flow cytometry GSH: glutathione HCG:
human chorionic gonadotropin H2n: HER-2/neu oncoprotein LASA-P: lipid-associated sialic acid in
plasma PR: progesterone receptor SI: synthesis index TPA: tissue polypeptide antigen UGF:
urinarygonadotropin fragment
*Presented at The Eighth Annual Ella T. Grasso Memorial Conference, Farmington, Connecticut,
November 14, 1990
Address reprint requests to: Hugh R.K. Barber, M.D., Director, Dept. of Obstetrics and Gynecology,
LenoxHillHospital, 100 East 77th Street, NewYork, NY 10021
Copyright © 1991 by The Yale Journal ofBiology and Medicine, Inc.
All rights ofreproduction in any form reserved.HUGH R.K. BARBER
reality is that, although the treated patients are living longer and more comfortably,
the five-year survival rate has not been appreciably improved in the last two decades.
Carcinoma of the ovary is not a surgical disease. In the present state of our
knowledge and treatment modalities, however, surgery is the backbone oftreatment,
and the prognosis depends upon the size ofthe residual cancer following surgery. In
addition, surgery has obviously reached its limits, and any additional aggressive
surgerywill create an inordinate morbidity and mortality. It isbecomingobvious that
ovarian cancer, like many others, is really a systemic disease. Until 1970, it was
extremely rare to find carcinoma ofthe ovarymetastasizing to the liver parenchyma,
to the bone marrow, lung, or brain. Now that chemotherapy has changed the
longevityofthese patients, however, late recurrences are beginning tobe found, with
increasing frequency, in these organs. It is obvious that more attention must be given
to the long-term systemic treatment of ovarian cancer. It is time to explore the new
frontiers for ovarian cancer.
NATIONAL PROGRAM FOR THE CONQUEST OF CANCER: REPORT
OF THE NATIONAL PANEL OF CONSULTANTS ON THE CONQUEST
OF CANCER
Ralph W. Yarborough, Chairman ofthe Committee on Labor and Public Welfare
ofthe U.S. Senate, on November 27, 1970, stated, "Cancer is a disease which can be
conquered. Our advances in the field ofcancer research have brought us to theverge
of important and exciting developments in the early detection and control of this
dreaddisease, but as anation we have notput forth the effort necessary toexploitthe
full potential of these gains, nor have we made the proper effort to ascertain what
additional avenues of research should be opened. The National Program for the
Conquest of Cancer had been initiated by President Nixon who committed millions
ofdollars to this project over the next decade." A great deal has been accomplished,
but much more must be done. As scientists and clinicians look to the next decade,
they see certain areas that have been identified but need more development.
TUMOR MARKERS
Tumor markers have made a significant contribution to stimulating interest in cell
metabolism and pathophysiology. They have been particularly useful in monitoring
treatment; however, the markers have and will probably always have a disadvantage
in identifying an early tumor. To date, only two, human chorionic gonadotropin
(HCG) and alpha-fetoprotein, are known to be specific. They are also sensitive. The
others are not only not specific, but they are not very sensitive. It is, however,
important to review their background andwhat they represent.
The problem with tumor markers as a means ofmaking a diagnosis is that a tumor
marker is developed from a certain volume oftumor. By that time, it is no longer an
early but rather a biologically late tumor.
Serum assays for tumor markers, most notably cancer antigen 125 (CA125), have
been evaluated as a meansofdecreasing the need forsecond-looklaparotomy. There
is now abundant evidence that when the CA125 level is normal, many patients still
harboroccult tumor. Almost allpatients have a significant amountoftumorwhenthe
CA125 level is elevated.
By the time a tumor has reached the size of one cubic centimeter, there are a
billion cells present. That size requires 30 population doublings. Although it is not
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directly known how long the doubling time for ovarian cancer is, since this type is a
heterogeneous tumor with different clones of cells present, it may be assumed that
the doubling time might encompass 30 to200ormore daysto reach the size ofa cubic
centimeter. It may be regarded clinically as an early tumor, but, in reality, it is
biologically a late tumor. A question that remains to be answered, but which may
offer an explanation for some unanswered questions, is that some of these multiple
clones present in ovarian cancer may contain metastasizing phenotypes; if so, it is
conceivable that a metastasis may occur in the first ten to 20 doubling times. The
author therefore believes that the role of the tumor marker will be for monitoring
treatment and unfortunately will not be able to serve as a predictable means for
making an early diagnosis.
Alpha-Fetoprotein (AFP)
AFP is an enzyme immunoassay measuringprotein associated with fetaltissue and
malignancy. It is elevated in primary tumors of the liver and non-seminomatous
testicular germ-cell tumors; it is particularly important to the gynecologic oncologist
when dealingwith an endodermal sinus tumor ofthe ovary.
CancerAntigen 125 (CA125)
CA125 is an immunoradiomometic assay using the monoclonal antibody OC125,
with 88-90 percent sensitivity in detecting non-mucinous epithelial ovarian carci-
noma and 60 percent sensitivity in detecting uterine cancer. It is an assay developed
by Bast et al. [3], who began to use monoclonal antibodies to identify antigens
circulating in the blood of patients with ovarian cancer. The one hundred and
twenty-fifth monoclonal antibody screened was designated OC125, and its antigenic
determinant was called CA125. The presence of CA125 antigenic determinant in
serum can be identified only by the OC125 antibody and is measured by immunoas-
say. The surface epithelium of normal fetal and adult ovaries does not express the
CA125 antigenic determinant, except in the presence of an inclusion cyst, areas of
metaplasia, and papillary excrescences. This finding makes the CA125 test valuable
in the diagnosis of ovarian cancer, particularly in monitoring therapy for this
malignancy.
CarcinoembryonicAntigen (CEA)
CEA is an enzyme immunoassay, using a monoclonal antibody against glycopro-
tein produced by immature and/ormalignant cells that originate in the gut. Elevated
values are associated with carcinomas of the rectum, colon, lung, and breast. It
probably has its greatest value in monitoring therapy for gastrointestinal tract
tumors.
Dianon MarkerNB/70K(DM170KorNB/70K)
This test is a radioimmunoassay for detecting human ovarian tumor-associated
antigen NB/70K, using the monoclonal antibody NB 12123. A sensitivity of 70
percent is found in ovarian carcinoma [4]. Elevated levels have also been associated
with other gynecologic malignancies, as well as with carcinoma of the lung and
breast.
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Human Chorionic Gonadotropin, Beta Sub-Unit (HCG)
HCG is an enzyme immunoassay measuring hormone ordinarily made by the
placenta and used as an indicator ofpregnancy. HCG is also produced by tumors of
germ-cell origin, such as testicular and ovarian tumors, aswell as some lung cancers.
It is particularly important in evaluating gestational trophoblastic neoplasias.
Lipid-Associated SialicAcid in Plasma (LASA-P Test)
LASA-P test is a biomarker, useful in a wide range of malignancies, that reflects
alteration in the surface membrane of malignant cells. The LASA-P test measures
total gangliosides and glycoproteins by the biochemical extraction and partition
method of Katopodis and Stock [5]. Sensitivities range between 77-97 percent,
depending on the cell of origin of the neoplasm. Studies have shown improved
predictive value when the LASA-P test is combined with other biomarkers and
biomarker profiles.
TissuePolypeptideAntigen (TPA)
TPA is an immunoradiomometic assay utilizing molecules derived from the
cytoskeleton ofepithelial cells. TPAis useful in the management ofmanycancers. In
prostate cancer, TPA has been shown to be a reliable marker for estimating
prognosis. Patients with normal TPA values at the time of diagnosis have a longer
survival than those with elevated values. The assay's value is being explored for the
study ofovarian malignancy.
Urinary Gonadotropin Fragment (UGF)
UGF is a small peptide present in the urine and tissues of patients with gyneco-
logic cancers. It is used as a tumor marker, particularly in the diagnosis of ovarian
cancer. Clinical observations were reflected at each clinic visit by UGF alone in 67
percent, by CA125 alone in 57 percent, and by UGF and CA125 together in 87
percent of cases. When evaluated separately, UGF and CA125 levels predicted 71
percent and 57 percent, respectively; together they forecast 86 percent of recurrent
cancers prior to clinical manifestations. UGF and CA125 should be used together in
the detection and management of ovarian cancers. This marker adds another
dimension to monitoring therapyfor patientswith ovarian cancer.
Dianon Systems Incorporated [6] has proposed a breast cancer profile that can
alsobe used forstudying the prognosis forovarian cancer. Thisprofile consists ofthe
DNA index (DI), cell cycle distribution (CCD), and synthesis index (SI), as well
as estrogen and progesterone receptors, epidermal growth factor receptor, and
HER-2/neu oncoprotein (H2n).
ONCOGENES
Oncogenes traditionally have been defined as genes able to confer on cells the
property of unregulated growth. All known oncogenes are derived from "proto-
oncogenes," their genetic counterparts, which are normally found in all mammalian
cells and generally play a role in normal processes ofcell growth and differentiation.
In the past, oncogenes have been considered to be good genes that have gone bad.
Recently this view has been challenged. It is reported that oncogenes are not "bad"
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genes, but "good" genes that have been altered, inappropriately expressed, or
inappropriately inactivated [7].
Oncogenes fall into a few general categories: those involved in phosphorylation,
those that regulate growth, those that play a role in protein transcription, and those
involved in DNA replication.
The protein product of each is found in that part of the cell best suited to its
activity. The src protein, a protein kinase, spans the cell membrane; the myc protein,
which controls messenger RNA, operates in the nucleus.
When proto-oncogenes undergo certain genetic alterations (including point muta-
tions, insertions, deletions, and translocations), the normal control of growth and
differentiation may change to the promotion of neoplastic development. The pres-
ence of oncogenes was originally assessed on the basis of their ability to induce
transformation to a malignant phenotype in tissue culture (elevated through morpho-
logic changes) or tumorigenicity when cells expressing those genes were introduced
into animals.
Although most studies have been directed to the ability of oncogenes to cause
uncontrolled growth of cells, and thereby the development of tumors, it is now
accepted that uncontrolled growth, taken alone, does not confer on a tumor the
property of being either benign or malignant. Other properties of malignant cells,
including the ability to metastasize and resistance to chemotherapy and radiother-
apy, are more important than the simple growth properties in determining whether
therapy of a patient with cancer will be successful. The development of the changes
in tumor cells that lead to a more malignant phenotype is known as tumor progres-
sion.
In recent years, investigators have studied the capacity ofoncogenes to lead to two
properties ofmalignant cells: (1) the ability to metastasize, and (2) the development
ofradiation resistance. Parallel to this research, there have been cytogenetic changes
in the transformed cells that have been investigated in the sites of oncogene
integration into the host genome, and there have been attempts to correlate such
genetic events ofthe biologic properties of the transformed cells.
HER-2/neu oncoprotein (H2n) is an investigational assay for a protein product of
the HER-2/neu oncogene. Amplification in this gene is significantly greater in
patients with early relapse and poor survival. In node-positive breast disease, this test
may predict outcome better than either estrogen or progesterone receptors. The
standard range for HER-2/neu-positive is greater than 5 femtomoles/mg protein.
The HER-2/neu proto-oncogene is amplified in 25 to 30 percent ofhuman primary
breast cancers, and this alteration is associated with disease behavior. In studies [8],
several similarities were found in the biology of HER-2/neu in breast and ovarian
cancer, including similar incidents of amplification and direct correlation between
amplification and overexpression, evidence oftumors in which overexpression occurs
without amplification, and the association between gene alteration and clinical
outcome.
Berchuck and his colleagues have recently reported [9] on the overexpression of
HER-2/neu associated with poor survival and advanced epithelial ovarian cancer.
They used the immunohistochemical technique involving a monoclonal antibody
specifically reactive with the external domain of HER-2/neu to study expression of
the HER-2/neu in frozen sections of normal ovary and advanced epithelial ovarian
cancer. They found that survival with a high HER-2/neu expression was significantly
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less than that of a control group and, in addition, was less likely to have a complete
response to primary therapy. It is obvious from all ofthese findings that HER-2/neu
deserves further evaluation as a prognostic marker in epithelial ovarian cancer.
FLOW CYTOMETRY (FCM)
This technique has provided investigators with a reproducible method for measur-
ing single-cell fluorescence. Flow cytometry uses an instrument which consists of a
source of light, usually a laser; light detectors or photomultiplier tubes; and a
computer, which serves as a signal-processing system. Chemical stains for cellular
components are utilized in order to make specific measurements.
Flow cytometry uses a focused beam oflight from a laser to strike the cells as they
pass, in single file, through the sample chamber. The scattered light is measured on
the photodetector, and, after the light passes through a series of filters and lenses,
the fluorescent signal is picked up by photomultiplier tubes. The electrical signal
from the photomultiplier tubes is then processed by the computer.
Fluorescence isusedbecause theblue-excitedyellow-greenfluorescence offluores-
cein is easier to discriminate from autofluorescence. The focused laser beam
provides illumination.
Among the properties of cells that can be measured using flow cytometry are the
size, internal structure (such as granularity), DNA and RNA content, viability, cell
shape, protein content, and a variety of internal and surface biomarkers. The data
from the computer are usually presented as a frequency histogram, which serves to
rendercomprehensible the data from measurements on thousands ofindividual cells
or nuclei.
The results obtained by the flow cytometry can be measured using other methods.
The advantage offlow cytometry, however, lies in its ease ofmeasurement, reproduc-
ibility, and in the fact that it provides multi-parameter single-cell analysis, which
permits direct assessment ofcellular heterogeneity.
Since it is possible to provide multiple analyses on single cells, flow cytometry
allows the description ofcellular heterogeneity, establishing the biologiccounterpart
of clinical heterogeneity common to most tumors. With the ability to analyze DNA
content, which is a reflectionofcell ploidy, there is now a method forestablishing the
prognosis of many solid tumors. Many useful flow cytometry assays exist, and the
important ones in oncology include:
1. Markers of malignancy, useful as an adjunct in the diagnosis of cancer and
the detection ofminimal disease
2. Cytokinetic markers, which can be used to describe tumor growth and hence
tumor aggressiveness
3. Markers of cellular differentiation, which have been used to characterize
tumor cells-at this time, predominantly in the hematologic malignancies
Following work using the Feulgen technique for staining DNA, studies have been
directed to identify the close relationship between chromosome number and nuclear
DNA content, as measured by flow cytometry. It is now accepted that the best
evidence for the diagnosis of malignancy is the description of the clonal chromo-
somal abnormality. The relationship between DNA content and chromosomal
abnormalities is the keystone for many studies in the field ofoncology.
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Flow cytometry provides a reproducible quantitation of single-cell DNA content
and the description of a population ofcells based on modal DNA content, usually in
the G1/0 phase ofthecell cycle. Thisfindingcan be compared to the DNAcontent of
normal cells (usually a contaminant of tumor samples) and expressed as the DNA
index, which may be equal to one (diploid), greater than one (hyperdiploid), or less
than one (hypodiploid).
Abnormal DNA content is referred to as aneuploidy, and this condition is
associated with an aggressive tumor. Currently, about 70 percent of human solid
tumors display aneuploid DNAcontent.
At this time, flow cytometry has provided an easy and reproducible analysis of
DNA content that directly reflects cell ploidy. Aneuploidy, a stable marker of
malignancy, is present in more than 70 percent of solid tumors. Its value as an
independent marker for prognosis is suggestive, but more work needs to be done to
produce hard data on this observation. Flow cytometry's great contribution is that it
provides multiple analyses of single cells and permits the description of cellular
heterogeneity, which forms the biological counterpart of the clinical heterogeneity
that clinicians deal with in practice.
FAMILIAL OVARIAN CANCER
Formanyyears, there hasbeen an awareness that ovarian cancers seem to occur in
families with more frequency than chance alone would indicate.
F.P. Li, A.H. Rapoport, J.F. Fraumeni, Jr., and R.D. Jensen reported on familial
ovarian carcinoma inJAMA4 in 1970 [10]. Since then, there have been many articles
on this subject. Recently, Piver and his colleagues at the Roswell Park Memorial
Institute in Buffalo, New York, have established the Familial Ovarian Cancer
Registry. Piver has reported on the familial ovarian cancer syndrome, stating that it
includes an earlier than usual age at diagnosis, as compared to the sporadic cases
(average age, 47 versus 53 years); a histologic diagnosis of poorly differentiated
serous adenocarcinoma; an autosomal dominant pattern ofinheritance withvariable
penetrance; transmission in a vertical fashion from either parent; and a uniformly
poor prognosis, with less than 10 percent of the women surviving for more than five
years. Lynch has also contributed a great deal to research on the problem ofgenetics
and the cancer patient.
Lynch and his colleagues [11] have described three different genetic and heredi-
tary syndromes in ovarian cancer patients:
1. Women at risk for developing only ovarian cancer
2. Women at risk for developing breast and ovarian cancer
3. The cancer family syndrome, in which men are at risk for developing
adenocarcinoma ofthe colon andwomen are at riskfordeveloping adenocar-
cinoma ofthe colon, ovary, and uterus
Because of the autosomal dominant nature of the inheritance of these familial
syndromes, the risk for female first-degree relatives of affected patients can be as
high as 50 percent. When only one first-degree blood relative has been treated for
common epithelial ovarian cancer, it is the author's opinion that the risk factor for
such apatientwould be in the range of5 percent and no greater than 10 percent. The
50 percent figure relates to at least two first-degree blood relatives, who are mother,
sister, or daughter. If, however, any of these patients has a cancer in her late 30s or
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early 40s, the author believes that the occurrence of cancer in these first-degree
blood relatives in the premenopausal years increases the riskfactor, but that it is not
as high as 50 percent.
A Familial Ovarian Cancer Registry, established in 1981, continues to add families
which contain two or more relatives with ovarian cancer [12]. As ofAugust 1989, the
newsletter of the Familial Ovarian Cancer Registry states that there are 222 families
that have been listed in the Registry, accounting for more than 539 patients with
ovarian cancer. In addition, there are 95 additional families, forwhom the Registryis
verifying that there are two or more first-degree relatives with ovarian cancer. The
Registry concludes that familial ovarian cancer should no longer be regarded as a
rare occurrence.
The newsletter also states that geneticcounseling for a prophylacticoophorectomy
should be done at the timewhen a woman has completed her familybut no later than
age 35. This stage is crucial to all women with a familial history of ovarian cancer,
because the disease occurs most commonly in sister-sister and mother-daughter
pedigrees. Sisters and daughters in families with a history of familial ovarian cancer
(two or more first-degree relatives) have a 50 percent chance of developing the
disease. This rate compares to a 1.4 percent chance in women without such family
history, or only one out of every 70 newborn females in the United States. In view of
these statistics, genetic counseling should start in the early twenties, and actual
physical surveillance should begin in the early thirties. Physical surveillance consists
ofpelvic and abdominal examinations and a CA125 assay every sixmonths and pelvic
or vaginal ultrasound every year. Similar genetic counseling and surveillance should
include women whose mothers and grandmothers, mothers and maternal aunts, two
or more aunts, or an aunt and a daughter developed ovarian cancer.
In addition to the CA125 marker, another serum marker reported is measurement
of the serum level of alpha-L-fucosidase. Fucosidosis is an autosomal recessive
storage disease due to a deficiency of alpha-L-fucosidase activity in tissues and body
fluids. The mechanism controlling levels of the enzyme in serum is unknown. The
quantity of alpha-L-fucosidase activity in the serum of humans apparently is deter-
mined by heredity. An individual may inherit either low, intermediate, or high
activity of alpha-L-fucosidase in serum. Low enzyme activity (< 100 U alpha-L-
fucosidase/ml serum), intermediate activity (100-274 U alpha-L-fucosidase/ml), and
high activity (.275 U/ml) are the levels usually reported. About 8 percent of the
general population have low enzyme activity in serum. It has been reported that
females with low activity of alpha-L-fucosidase in serum were three times more
common among ovarian cancer patients than among healthy females. This finding
suggested that low activity of alpha-L-fucosidase in serum of females may be a
hereditary condition, associated with increased risk of developing ovarian cancer. A
study ofthis condition may contribute to understanding ofthe clinical features ofthe
familial ovarian cancer syndrome. Wench and his colleagues have found that, even
though several family members with ovarian cancer did manifest a decrease in
enzyme activity, the association was not specific enough to assign risk based on this
marker alone. Therefore, great caution must be exercised in interpreting the results.
SEX STEROID RECEPTORS
Sex steroid hormone receptors provide the means by which estrogen and progest-
erone influence their target tissues. Receptor assays have proved clinically useful in
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the management of breast cancer. Although much research had been done on
receptors, it was Jensen et al. [13], working with breast tissue, who brought this
research to fruition. Receptor assays, as theyapply to the studyofovarian cancer, are
currently receiving a great deal of intensive investigation. Although estrogen and
progesterone receptors have been widely used clinically to identify tissues sensitive
to estrogen and progesterone, new applications are beingexplored.
The ovaries are identified with producing sex steroid hormones, particularly
estrogen and progesterone, and their production is regulated by the pituitary.
Studies have shown that ovarian epithelial malignancies do contain all classes of
steroid hormone receptors. Since these receptors have been found in relatively low
concentrations, it is more difficult to work with them than it is to work with breast
tissue. Reports have shown that ovarian carcinoma grown in long-term tissue culture
has proved to contain both estrogen and progesterone receptors and may become a
model for studying the action ofsteroid hormones in ovarian cancer. It may soon be
possible to conduct a formal trial of endocrine therapy in order to explore the
correlation of receptor datawith response to therapy.
Research has shown that normal lymphocytes can be stimulated to produce
glucocorticoid receptors and that the induction of these receptors correlates with
increasing sensitivity to glucocorticoid therapy. This finding could add another
modality to the therapy of ovarian cancer if it is possible to produce estrogen and
progesterone receptors on ovarian cancercells. Studies nowunderway are investigat-
ing the coupling of cytotoxic agents to steroid hormones, and the administration of
this new endocrine-chemotherapy molecule to patients whose tumors contain the
appropriate steroid hormone receptor. If this process can be developed, it has the
potential for delivering large quantities of cytotoxic drug directly to the hormone-
sensitive tumor. It would also have the potential for imaging with radioactive
isotopes. Granted that it is in its infancy, bringing it to fruition would be a great
advance in therapy.
The estrogen receptor (ER) test measures receptor expression and reports the
tumor asestrogenreceptor-positive orestrogenreceptor-negative. Estrogenreceptor-
negative tumors are aggressive and rarely respond to endocrine therapy. Estrogen
receptor status is a strong, independent predictor of recurrence and survival. The
reference range for an estrogen receptor-negative patient is less than 10 femtomoles
ER/mg cytosol protein. Progesterone receptor (PR) expression is also reported as
positive or negative. Some researchers report that progesterone receptors have
greater predictive value than estrogen receptors and are better correlated with the
outcome ofendocrine therapy. Progesterone receptor-positive findings may indicate
false-negative estrogen receptor results. The reference range for progesterone
receptor-negative is less than 10 femtomoles PR/mg cytosol protein.
Epidermal growth factor receptor (EGFR) is an investigational assay. EGFR-
negative tumors carry a prognosis similar to that of ER-positive disease, even in
ER-negative tumors. Ninety percent of EGFR-positive tumors are ER-negative.
EGFR-negative status may thus define a subgroup of ER-negative patients with
better survival rates. The reference range for epidermal growth factor receptor is
EGFR-negative less than 5 femtomoles/mgprotein.
CHEMOTHERAPY
In contrast to surgery and radiationtherapy, chemotherapy, which is the treatment
of cancer with drugs, hormones, and anti-hormones, can be used effectively for
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disseminated as well as localized cancer. Chemotherapy has become a reality only in
the past 30 to 40 years. Each of these decades has seen some important advances in
the number of compounds available and in the spectrum of their usefulness. Within
the last two decades, it has become clear that, although chemotherapy had long been
considered largely a palliative procedure, capable of extending but not saving lives,
certain kinds of cancer can now be cured by chemical treatment. A major goal of
current cancer chemotherapy is to achieve cures by prompt and vigorous treatment
of such cancers.
Combinations of chemotherapeutic agents have been used with substantial suc-
cess, particularly when each of the drugs used acts on the cancer cell in a different
way. Major improvements in the treatment of certain types of cancer have been
achieved both by using several of the active drugs simultaneously and by using
different drugs in sequence.
Chemotherapy now constitutes a major and indispensable therapeutic approach,
capable of producing cures, in particular kinds of metastatic cancer. The problem
with chemotherapy is that it is a systemic treatment that affects normal as well as
cancer cells. Organs such as the hematopoietic system and the gastrointestinal
system, with a rapid turnover of cells, receive the greatest damage to normal cells
from chemotherapeutic agents.
Chemotherapy can occasionally produce cures in a broad spectrum of cancer
types. The cancers that can be cured by chemotherapy are not always those which
grow most rapidly. Not all derive from the same primitive embryonic tissue; many
organ classes are represented. Furthermore, curative chemotherapy is not always a
product of a single drug nor a single technique of drug use. Rather, many different
drugs are involved, sometimes in combination with each other, sometimes in
combination with surgery and radiation. This high degree of specificity between a
particular tumor and a particular drug or drug combination implies that no universal
chemotherapeutic cure is to be anticipated. The complexity of special drugs and
regimens for special tumors can also be construed to mean that a drug that fails in the
treatment of one kind ofcancer may exhibit major activity against another.
The sensitivity of cancer cells to drug action is dependent on a variety of possible
factors, not all of which are known. The drug must reach the cancer cell surface,
enter the cell, remain active or undergo necessary activation, reach a critical target
site, and combine with it at a time when chemical processes on which the cell
depends for its viability or reproduction are in progress. Furthermore, competing
and bypass pathways in the cell must not be able to compensate for the chemical
injury which the drug inflicts. Failure ofthe whole chain of events can result from the
failure of any one step. Thus, any drug given by the wrong regimen to a mass of
cancer cellswhich are biologically insusceptible to its action at that time is a failure of
chemotherapy. Better drug design and better understanding ofthe biological charac-
teristics of each cancer type, and, indeed, of each cancer, will advance the effective-
ness ofchemotherapy.
Although the platinum compounds were introduced in 1965, it was not until 1979
that they became the keystone of treatment for carcinoma of the ovary. Since the
initial compound cis-platinum, another platinum compound, carboplatinum, has
recently been developed; it produces less nausea and vomiting but still maintains its
therapeutic value.
An interesting new analogue of cisplatin that is being evaluated is ormaplatin,
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which was formerly termed tetraplatinum. It is a second-generation platinum ana-
logue, which has less nephro- and neurotoxicity than cisplatin. Ormaplatin has been
found to be more potent than cisplatin when tested against various human ovarian
cell lines that have become resistant to cisplatin.
Ifosfamide, too, has been introduced, and, although it is mainly indicated for
third-line chemotherapy of germ-cell testicular tumors, it is being used for the
management ofovarian cancer, particularlywhen other first-line agents have failed.
It should ordinarily be used in combination with a prophylactic agent for hemor-
rhagic cystitis, such asmesna. Ifosfamide is a drugthat hasmarked toxiceffects, but it
is hoped that, as the scientists and clinicians learn to use it, particularly in combina-
tions with other drugs, its anticipated response against ovarian cancer will probably
be achieved.
Etoposide has been introduced for the management ofrefractory testicular tumors
and small-cell lung cancers. It is, however, being used in combination with other
drugs for the management of ovarian cancer. Etoposide has a marked hematologic
toxicity as well as gastrointestinal toxicity.
A new regime called the VIP regime has been introduced for the treatment of
persistent and recurrent carcinoma of the ovary. The V is Vepesid&', which is
etoposide, also known as VP-16; the I is Ifexa', which is ifosfamide; and the P is
Platinol'@, which is cisplatin. Although this combination is highly toxic, in the hands
ofqualified oncologists it is adding a new dimension to the treatment ofpersistent or
recurrent ovarian cancer.
Taxol is a new drug that is undergoing clinical trial and is sponsored by the
Division of Cancer Treatment (DCT), ofthe National Cancer Institute. It is a novel
diterpene compound derived from the bark of the western yew, Taxus brevifolia. In
1977, taxol was chosen for development as an anti-neoplastic agent because of its
unique mechanism of action and good cytotoxic effect against the intraperitoneally
implanted B16 melanoma and the human MX-1 mammary tumor zenograft. Taxol
inhibits normal cellular replication in vitro by promoting microtubule assembly and
stabilizing tubulin polymeres against depolymerization. Clinical trials began in 1983
and have recently been expanded. A limiting factor may be that the western yew is
becoming an endangered species.
Currently, taxol is not produced by any ofthe pharmaceutical companies, and the
centers that have been approved for its use are producing their own drug. Since the
drug is available in limited quantities and isbeingevaluated forvarious tumors, there
are very fewprojects, but it is being used against ovarian cancer. There are, however,
some projects, and the anticipated reportswill, it is hoped, add another dimension to
the management ofovarian cancer.
The cost of research directed to finding new drugs, the problem of litigation, and
the resistance by the FDA to release drugs until they have been put through a long
series of phase 1, 2, and 3 trials before authorizing their use has made anti-cancer
drug research less desirable for the large pharmaceutical companies. Perhaps some
of these problems can be solved. Until that time, scientists will direct attention to
fitting the ideal combination of available anti-cancer drugs to produce additional
cures in the management ofcarcinoma ofthe ovary.
Modulators ofToxicity
Drugs are being evaluated to reduce toxicity of the current chemotherapy agents.
Diethyldithocarbamate (DDTC) has been demonstrated to protect against many of
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the toxic effects of platinum-based compounds without interference in their anti-
cancer effect. WR 2721, an aminothiol, is another protective agent being evaluated
with platinum compounds. An analogue ofACTH (Org 2766) is being tested for the
prevention of cis-platinum-induced neurotoxicity. Ondansetron is widely used in
Europe and has recently become available in the U.S. It has the potential to
eliminate cisplatin-induced nausea andvomiting.
Modulation ofDrugResistance
Glutathione (GSH) has been identified as a mediator of cellular resistance to
alkylating agents and platinum-based compounds. A synthetic amino acid, buthion-
ine sulfoximine, blocks glutathione synthesis. Amphicodin is an inhibitor of DNA
polymerases alpha and gamma; it inhibits the ability of the cell to repair DNA
damage by anti-cancer drugs.
Multiple DrugResistance in Cancer
Kartner and Ling [14] have suggested that an ancient pump protein that flushes
toxin out of cells may be the reason that cancer chemotherapy fails. They have
identified a mechanism and have suggested that multi-drug-resistant cancers may be
made vulnerable again. Kartner and Ling suggested that, ifthere were not some sort
ofpump that could flush toxins out ofcells, human beingswould have vanished from
this earth ages ago. The work of many researchers slowly accumulated to enable
them to formulate their theory. A series of experiments led them to believe that
multiple drug resistance appeared to result from a single mutation. Their theorywas
that a single gene could account for the multiple resistance to unrelated drugs.
Working with various systems, they found that cells which were resistant to a drug
somehow excluded it. This observation suggested a mechanism for the drug resis-
tance; that is, there appeared tobe somebarrierthatkept the drugfrom reaching the
interior of the cell, where it would produce its lethal effect. Two possible theories
were explored. One theory proposed that a permeability area prevented drugs from
entering the cells. The other suggested that an efflux pump (a mechanism that
actively pumped drug out of the cell once it got inside) was at work in the resistant
cells; this model was based on the observation of the kinetics of drug flow into and
out ofthe cells. It was found thatwhen a resistant cellwas temporarilypoisoned with
cyanide to inhibit energy production, the cell behaved like a drug-sensitive cell; it
could not keep out the drug. When the cyanide was washed out and normal
metabolism was restored, the cell could once again exclude the drug. Furthermore,
the cell was then able to pump out the drug that had accumulated while it was
poisoned. Hence, an energy-dependent drug-efflux pump seemed to be the simplest
explanation.
Theexpression of170,000daltonplasmamembraneproteindesignatedP-glycopro-
tein, or P 170, seems to be associated with multi-drug resistance of cells to
anti-cancer chemotherapy. P-glycoprotein is the gene product of the mdr 1 gene,
which has been found to be amplified in many cases of multiple-drug resistance.
P-glycoprotein has been found to increase drug resistance by serving as a pump,
actively removing drugs from the cell. Drug resistance may be partially blocked by
calcium channel blockers, such asVerapamilF, which bind to P-glycoprotein.
Although this is a highly logical explanation as to how drugs become resistant to
anti-cancer chemotherapy, in actuality it has been extremely difficult to prove;
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however, since the underlying logic is acceptable, more work must be done in this
area. There is hope that the theorymaybe refined, andways toblockthe effluxpump
maybe found.
BIOLOGICAL RESPONSE MODIFICATION [15]
The term "biotechnology" encompasses manyactivitieswhich have incommon the
fact that they all harness the fundamental abilities of living organisms. One of the
most impressive achievements ofscience has been the explosion ofknowledge about
the chemical composition of organisms and the way these chemicals interact to
create the phenomenon scientists recognize as life. Organisms are sometimes
compared to chemical factories. The strength of this analogy lies in its emphasis on
the chemical nature oflife-the fact that growth, development, and reproduction all
depend on chemical reactions. The analogy does, however, obscure some ofthe most
fundamental characteristics of organisms, many of which are directly related to
biotechnology.
GeneticEngineering
Ingeneticengineering, there is a reweavingofthe threads oflife. The possibilityof
transferring genes from one organism to another is an alluring prospect, since
genetic engineering can reduce the cost and increase the supply of an enormous
range of materials now used in medicine, agriculture, and industry. Furthermore,
there are many substances that occur naturally in only small quantities, which might
well prove invaluable if they were available in sufficiently large amounts for their
potential to be examined.
The biotechnological application of genetic engineering consists of four main
stages: obtaining thegenewhich codes forthe product that the microbial factory is to
manufacture; inserting the gene into the microbes; inducing the microbes to start
synthesizing the foreign product; and collecting that product.
The body's inherent biochemical capacity for killing cancer cells plus the new
genetic technology is called biologic response modification, or biomodulation, for
short. Biologic response modification is the new wave in cancer treatment, generat-
ing excitement among scientists, patients, and the public.
The use ofbiologics and biologic response modifiers in the treatment of cancer is
ofrecent origin. Biologics maybe defined as any product ofa mammalian organism,
and biologic response modifiers are those agents and approaches that alterbiological
response in the host-tumor interaction. The field includes traditional immunother-
apy but also encompasses the use of molecular biology, recombinant genetics, and
hybridoma technology, all ofwhich produce highly purified biologic substances with
anti-cancer activity. The recognition of growth, differentiation, and maturation
factors, as well as the possibility of making antagonist or competitive inhibitors to
factors that support neoplastic growth, infectious disease, and hereditary disorders
provides an additional biologic approach in the area.
Gene Therapy
Gene therapy is medicine's next frontier. It is now possible to locate a single gene,
of the organism's total DNA, which can be recombined with a carrier molecule of
DNA. It is now possible to introduce recombinant DNA into a bacterial cell in order
to produce an altered organism. Recombinant DNA technology, commonly referred
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to asgeneticengineering, hasprovided sciencewith the tools forthebiosynthesis and
subsequent mass production ofa significant number ofbiologicals. This work should
revolutionize the treatment of cancer over the next ten years. The process involves
incorporation (recombination) ofa segment ofa DNAmolecule containinga desired
gene into avector, usually a plasmid, which is, in turn, inserted into a host organism,
usuallyEscherichia coli, although other bacteria, yeast, fungi, sex cells, and mamma-
lian cells have been used. E. coli are cloned, and the organism producing the desired
protein or polypeptide is selected. This clone is mass-produced by fermentation
techniques, and the protein molecule is harvested and purified. The resultant
product is a highly purified protein solution, generally with greater than 95 percent
purity, and with a highly specific activity, containing the greatest possible amount of
biologic activity per milligram ofprotein.
There are a number ofbiologic response modifiers that are currently being used.
These include interleukins, thymic hormone, tumor necrosis factor, macrophage
activating factor, lymphotoxins, growth and transformingfactors, interferons, colony-
stimulating factors, and monoclonal antibodies.
Monoclonal antibodies are receiving a great deal of attention. They can function
as naked antibodies, as drug-carrying antibodies, and as radioactive antibodies.
Their potential is great, and more work needs to be done to make the monoclonal
antibody a diagnostic and therapeutic predictive modality.
No one has actually been cured by biologic response modifiers; however, meta-
static disease is not often curedbyanymeans. Medical ethics dictate that newtreatments
be tested on advanced cases when established treatments offer no hope. Thus, the
most difficult cases are used to test these substances. The future ofbiologic response
modifiers rests upon the answer to a crucial and fundamental question: What causes
the body to perceive harmful tumor antigen as self? Once the body has decided that
the tumor antigen is part ofitself, any attempt to destroy that balance will have only
limited success. Initially, the body recognizes a tumor antigen as harmful. It then
changes its decision and accepts that antigen as self. Thus, suppressive cells are
producedwhich inhibit the immune system's attempt to attackthe tumorcells. Drugs
can be used to reduce this suppression, but the effects are short-term. When it is
possible to understand why the body sees the tumor antigen as part ofitself, it would
then be possible to use biomodulation to intervene at that critical point. Until
scientists understandwhat is involved in the determination ofself, theywill not reach
their potential in treating patients bymodulating the immune response.
The author presents the sequential treatment plan for the management ofcancer:
Restore immunity to normal by treating the patient with a thymic hormone or
low-dose cyclophosphamide (has the ability to suppress the action of suppressor T
cells).
Give avaccine to stimulate the patient's own cells.
Activate the patient's immune cells to a greater degree with interleukin 2.
Monoclonal antibodies could then be used to target killer cells to their target
more effectively or to act ascarriersfor killermolecules (toxins, drugs, or radioactive
isotopes).
SUMMARY
The problem ofwhether ovarian cancerproduces metastasis or spread throughout
the abdomen or whether what appears to be carcinomatosis represents multiple
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primaries must be clarified. Woodruff has stated [16] that the ovary and the entire
pelvic and peritoneal cavities are mesothelial structures. Ifit can be determined that
carcinomatosis of the ovary represents multiple primaries, there is little chance for
producing an early diagnosis, and attention must then be directed entirely to the
treatment ofcarcinoma ofthe ovary [17].
The research in genetics shows promise for the potential of making an early
diagnosis and suggestive but not conclusive promise at this time for identifying the
high-risk patient.
Flow cytometry has furnished a relatively easy and inexpensive method ofprovid-
ing a profile for prognostic indicators in ovarian cancer. These include a DNA index
(DI), cell cycle distribution (CCD), synthesis index (SI), estrogen and progesterone
receptors (ER and PR), epidermal growth factor receptor (EGFR), and HER-2/neu
oncoprotein (H2n).
Gene therapy, genetic engineering, and the biologic response modifiers are in the
forefront ofthe new frontiers in ovarian cancer diagnosis and management.
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